FOXP3 and lung carcinoma: As a result, the proportion of GARP+ cell in Foxp3+ Tregs from lung cancer patients was almost similar with that from healthy donors [0.3390% (0.05325%, 0.7548%) vs. 0.4780% (0.2353%, 1.440%), P = 0.2306], while both of them were a very little bit higher than that in Foxp3− Tconvs from lung cancer patients [0.2315% (0.1368%, 0.3825%), P = 0.0011] and healthy donors [0.1155% (0.06775%, 0.2648%), P = 0.0059].